Myriad Genetics (MYGN) Tops Q1 EPS by 13c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
Myriad Genetics Reports Fiscal First-Quarter 2019 Financial Results
November 6, 2018 4:05 PM ESTTotal First-Quarter Revenues of $202.3 Million, Up 13 PercentFirst-Quarter Diluted EPS of ($0.01) and Adjusted EPS of $0.43, Up 48 PercentRevised Full-Year Revenue Guidance to $855 to $865 Million; Maintained Diluted EPS Guidance of $0.40 to $0.45 and Adjusted EPS Guidance of $1.70 to $1.75
SALT LAKE CITY, Nov. 06, 2018 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN, Myriad or the Company), a global leader in molecular diagnostics and personalized medicine, today announced financial results for its fiscal first-quarter 2019, provided an update on recent business highlights, revised its fiscal year 2019 financial guidance and provided fiscal second-quarter 2019 financial... More
